Guido Hegener

Guido Hegener is a Managing Partner at Digital Health Ventures / DHV Management GmbH, a Berlin-based venture capital firm focused on early-stage digital health investments. DHV’s own materials describe the firm as investing in “Digital Health Startups,” supporting founders with capital, a healthcare and technology network, and active portfolio work.

Before DHV, Hegener worked in the startup and venture ecosystem. MarketScreener lists him as a founder and Managing Director of dealvertise GmbH from 2011 to 2012, a Partner at XLHealth AG from 2013 to 2015, and Managing Partner at DHV Management GmbH from 2015. Deutsche Startups reported in 2012 that he was part of Dealvertise’s founding/management team and had previously worked at Rocket Internet.

His public LinkedIn profile lists DHV as his current firm, Berlin as his location, WHU - Otto Beisheim School of Management as part of his education, and long-running memberships with InPraxi e.V. and IdeaLab! e.V. He has also written publicly on digital health commercialization, telemedicine, trust, empathy, and B2B readiness for health startups.

Hegener is also connected to portfolio governance. Company and executive-profile sources list him as a director/board member at Liva Healthcare; Danish company-data listings show Guido Dominik Hegener joining Liva Healthcare Holding ApS’s board on March 11, 2019.

• DHV focuses on early-stage digital health startups and describes its mission as building a sustainable digital health ecosystem.
• The firm’s stated portfolio support model is active: it says it supports portfolio entrepreneurs and leverages networks in technology and healthcare.
• Hegener’s own writing emphasizes that many digital health startups need serious B2B/commercial readiness because partnerships with corporates, payers, providers, or other healthcare organizations can be essential to revenue.
• In his B2B-readiness article, he argues that founders should understand their partner universe, pain points, technical requirements, price points, implementation timeline, partnership goals, and organizational readiness before pursuing large healthcare partners.
• In his “digital empathy” writing, he highlights trust and empathy as core product questions in healthcare, asking founders to decide what levels of trust and empathy they need to offer while maintaining scalability.
• In telemedicine, he has argued that market choice matters because regulation, reimbursement, prescriptions, and consumer adoption vary significantly across European countries.